Antiviral Drugs Market Growth Rate, Global Trend, and Opportunities to 2026

1
Antiviral Drugs Market To Reach USD 71.48 Billion
By 2026
www.reportsanddata.com
sales_at_reportsanddata.com
2
Market Summary
Factors attributed to the growing CAGR and high
demand for the antiviral drugs market are higher
incidences of HIV and other life-threatening
diseases accompanied with product launches,
technological progressions and overall public
awareness regarding well-being of human
health Market Size USD 49.87 Billion in 2018,
Market Growth - CAGR of 4.6, Market Trends
Product launches along with effective RD
3
Our Approach
Market Summary

• According to the current analysis of Reports and
  Data, the global antiviral drugs market was
  valued at USD 49.87 billion in 2018 and is
  expected to reach USD 71.48 billion by year 2026,
  at a CAGR of 4.6. Antiviral drugs help to
  diminish the duration of flu symptoms in
  otherwise healthy children and adults and may
  lessen the severity of common flu symptoms.
  Antiviral drugs are medicines that reduce the
  intensity of flu viruses to reproduce. Most
  antivirals are used for specific viral
  infections, while a broad-spectrum antiviral is
  effective against a wide range of viruses.
  Antiviral drugs are suggested for both treatment
  and prevention of flu. Antiviral drugs work best
  when consumed within 48 hours of beginning of flu
  symptoms, but they may still offer benefits when
  taken later depending upon the nature of the flu.
  They may also reduce the risk of complications
  such as ear infections in children, respiratory
  complications requiring antibiotics, and
  hospitalization in adults. Viruses use the host's
  cells to replicate thus, creating a safe and
  effective antiviral drug is tough.
• Rising incidences of viral infection along with
  increase in public awareness, rise in healthcare
  expenditure, effective investments on RD and
  development of severe and life-threatening
  diseases is likely to foster the growth of the
  global antiviral drugs market. Furthermore, Huge
  target population is provided by increasing
  frequency of STIs caused by human
  immunodeficiency virus and human papillomavirus.
• Request for a sample of this research report _at_
  https//www.reportsanddata.com/sample-enquiry-form
  /1734

4
Our Approach
Market Summary

• Further key findings from the report suggest
• Growing incidences of HIV is likely to create
  higher demand for global antiviral drugs market.
  According to the statistics estimated by World
  Health Organization, around 70 million people
  have been infected with the HIV virus and about
  35 million people have died of HIV
• Complications of influenza, and other illnesses
  that resemble influenza, may require different
  treatment and in some cases, urgent medical
  attention which prescribes antiviral drugs for
  curation. Influenza viruses can become resistant
  to specific anti-influenza antiviral drugs, and
  all of these drugs may have side effects
• HIV segment in the applications is likely to hold
  the highest market share during the forecast
  period due to growing incidences of HIV
  infections across the globe. HIV held a market
  share of roughly, 49.1 in the year 2018
• Owing to the introduction of new and solid drugs
  along with effective RD practices, hepatitis
  registered as the fastest growing segment in the
  applications with highest compounded annual
  growth rate of 5.3
• To identify the key trends in the industry, click
  on the link below https//www.reportsanddata.com/
  report-detail/antiviral-drugs-market

5
Our Approach
Market Summary

• Key participants include Gilead Sciences, F.
  Hoffmann-La Roche AG, GlaxoSmithKline,
  Bristol-Myers-Squibb, AbbVie, Johnson Johnson,
  Merck Co., Aurobindo Pharma, Cipla, and Dr
  Reddys.
• For the purpose of this study, Reports and Data
  have segmented the Global Antiviral Drugs market
  on the basis of type, application, mechanism of
  action and region
• Type (Revenue, USD Million 20162026)
• Branded
• Generic

6
Our Approach
Market Summary

• Application (Revenue, USD Million 20162026)
• HIV
• Hepatitis
• Herpes Simplex Virus
• Influenza
• Others
• Mechanism of Action (Revenue, USD Million
  20162026)
• Reverse transcriptase inhibitors
• Nucleotide polymerase inhibitors
• Protease inhibitors
• Others
• Order Now https//www.reportsanddata.com/checkout
  -form/1734

7
About Us
Our Approach
About Us

• Reports and Data is a market research and
  consulting company that provides syndicated
  research reports, customized research reports,
  and consulting services. Our solutions purely
  focus on your purpose to locate, target and
  analyze consumer behavior shifts across
  demographics, across industries and help clients
  make a smarter business decision. We offer market
  intelligence studies ensuring relevant and
  fact-based research across a multiple industries
  including Healthcare, Technology, Chemicals,
  Power, and Energy. We consistently update our
  research offerings to ensure our clients are
  aware about the latest trends existent in the
  market. Reports and Data has a strong base of
  experienced analysts from varied areas of
  expertise.
• Contact Us
• John Watson
• Head of Business Development
• Reports And Data Web www.reportsanddata.com
• Direct Line 1-212-710-1370
• E-mail sales_at_reportsanddata.com